Form 4: Aerovate Therapeutics Officer Exercises Stock Options

Sentiment:

SEC Form 4 Filing


Benjamin T. Dake, an officer at Aerovate Therapeutics, exercised stock options to acquire common stock at a price of $1.74 per share.

Summary

  • On July 31, 2024, Benjamin T. Dake exercised stock options to acquire 11,454 shares of Aerovate Therapeutics common stock at $1.74 per share, and on August 1, 2024, he exercised options to acquire 1,507 shares at the same price.
  • Following these transactions, Dake directly owns 14,252 shares of common stock.
  • The stock options were granted on September 4, 2020, and vest over time.

Sentiment

Score: 5

Explanation: Neutral sentiment as it reports routine stock option exercises.

Industry Context

This is a routine Form 4 filing, indicating insider transactions related to stock options. It's common for officers to exercise vested options.

Stakeholder Impact

  • The exercising of stock options by an officer could have a minor dilutive effect on existing shareholders.

Key Dates

DateDescription
2020-09-04Date of grant for employee stock options
2024-07-31Transaction date for exercising stock options to acquire 11,454 shares
2024-08-01Transaction date for exercising stock options to acquire 1,507 shares
2030-09-03Expiration date of stock options

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.